Association of Naloxone Coprescription Laws with Naloxone Prescription Dispensing in the United States

JAMA Network Open

Volumn 2, Issue 6, 2019, Pages

  Sohn, Minji ^a   Talbert, Jeffery C ^b   Huang, Zhengyan ^c   Lofwall, Michelle R ^d   Freeman, Patricia R ^b  

^a FERRIS STATE UNIVERSITY   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; MORPHINE; NALOXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL AUDIT; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG INTOXICATION; DRUG LEGISLATION; DRUG OVERDOSE; HEALTH CARE ACCESS; HUMAN; INCIDENCE; MORTALITY RATE; OUTCOME ASSESSMENT; PHARMACY (SHOP); POPULATION; PRESCRIPTION; PRIORITY JOURNAL; TIME TO TREATMENT; UNITED STATES; CLINICAL PRACTICE; LONGITUDINAL STUDY;

ANALGESICS, OPIOID; DRUG OVERDOSE; DRUG PRESCRIPTIONS; HUMANS; LONGITUDINAL STUDIES; NALOXONE; NARCOTIC ANTAGONISTS; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 85067892545     PISSN: None     EISSN: 25743805     Source Type: Journal    
DOI: 10.1001/jamanetworkopen.2019.6215     Document Type: Article

References (31)

1. Chen Q, Larochelle MR, Weaver DT, Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open. 2019; 2 (2): e187621. doi: 10.1001/jamanetworkopen.2018.7621 30707224
2. Centers for Disease Control and Prevention. Drug overdose deaths in the United States, 1999-2017: NCHS Data Brief No. 329. https://www.cdc.gov/nchs/products/databriefs/db329.htm. Published November 28, 2018. Accessed February 7, 2019.
3. Ashburn MA. The evolution of prescription drug monitoring programs. Pharmacoepidemiol Drug Saf. 2016; 25 (7): 852-853. doi: 10.1002/pds.4036 27222197
4. Pauly NJ, Slavova S, Delcher C, Freeman PR, Talbert J. Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. Drug Alcohol Depend. 2018; 184: 26-32. doi: 10.1016/j.drugalcdep.2017.12.002 29402676
5. Bateman BT, Choudhry NK. Limiting the duration of opioid prescriptions: balancing excessive prescribing and the effective treatment of pain. JAMA Intern Med. 2016; 176 (5): 583-584. doi: 10.1001/jamainternmed.2016.0544 27043188
6. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014; 8 (3): 153-163. doi: 10.1097/ADM.0000000000000034 24874759
7. Prescription Drug Abuse Policy System. Naloxone overdose prevention laws. http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139. Updated July 1, 2017. Accessed July 9, 2018.
8. Davis C, Carr D. State legal innovations to encourage naloxone dispensing. J Am Pharm Assoc (2003). 2017; 57 (2S): S180-S184. doi: 10.1016/j.japh.2016.11.007 28073688
9. Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018; 189: 37-41. doi: 10.1016/j.drugalcdep.2018.04.020 29860058
10. Freeman PR, Hankosky ER, Lofwall MR, Talbert JC. The changing landscape of naloxone availability in the United States, 2011-2017. Drug Alcohol Depend. 2018; 191: 361-364. doi: 10.1016/j.drugalcdep.2018.07.017 30195192
11. Adams JM. Increasing naloxone awareness and use: the role of health care practitioners. JAMA. 2018; 319 (20): 2073-2074. doi: 10.1001/jama.2018.4867 29621389
12. US Surgeon General's advisory on naloxone and opioid overdose. HHS.gov website. https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html. Accessed February 13, 2019.
13. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016; 315 (15): 1624-1645. doi: 10.1001/jama.2016.1464 26977696
14. Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. HHS Publication No. (SMA) 18-4742. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
15. Vermont Secretary of State. Statutes & rules. https://www.sec.state.vt.us/professional-regulation/list-of-professions/pharmacy/statutes-rules.aspx. Accessed November 19, 2018.
16. Virginia Register of Regulations. 18VAC85-21. Regulations governing prescribing of opioids and buprenorphine (adding 18VAC85-21-10 through 18VAC85-21-170). http://register.dls.virginia.gov. Accessed November 16, 2018.
17. IQVIA. https://www.iqvia.com. Accessed April 14, 2018.
18. Automation of Reports and Consolidated Orders System (ARCOS) Retail Drug Summary Reports. Drug Enforcement Administration, US Department of Justice. https://www.deadiversion.usdoj.gov/arcos/. Accessed June 9, 2018.
19. Centers for Disease Control and Prevention. Data Resources: analyzing prescription data and morphine milligram equivalents (MME). https://doc.arcgis.com/en/esri-demographics/data/census-acs.htm. Accessed June 9, 2018.
20. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370 (22): 2063-2066. doi: 10.1056/NEJMp1402780 24758595
21. Centers for Disease Control and Prevention. CDC WONDER. http://wonder.cdc.gov. Accessed February 7, 2019.
22. VanHouten JP, Rudd RA, Ballesteros MF, Mack KA. Drug Overdose Deaths Among Women Aged 30-64 Years-United States, 1999-2017. MMWR Morb Mortal Wkly Rep. 2019; 68 (1): 1-5. doi: 10.15585/mmwr.mm6801a1 30629574
23. Gupta R, Shah ND, Ross JS. The rising price of naloxone: risks to efforts to stem overdose deaths. N Engl J Med. 2016; 375 (23): 2213-2215. doi: 10.1056/NEJMp1609578 27959694
24. Hubbard AE, Ahern J, Fleischer NL, To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010; 21 (4): 467-474. doi: 10.1097/EDE.0b013e3181caeb90 20220526
25. Lee J-H, Han G, Fulp WJ, Giuliano AR. Analysis of overdispersed count data: application to the Human Papillomavirus Infection in Men (HIM) Study. Epidemiol Infect. 2012; 140 (6): 1087-1094. doi: 10.1017/S095026881100166X 21875452
26. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013.
27. Ostrov BF. More states say doctors must offer overdose reversal drug along with opioids. Kaiser Health News. February 2019. https://khn.org/news/more-states-say-doctors-must-offer-overdose-reversal-drug-along-with-opioids/. Accessed February 26, 2019.
28. Fischer MA, Stedman MR, Lii J, Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010; 25 (4): 284-290. doi: 10.1007/s11606-010-1253-9 20131023
29. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008; 14 (6): 553-560. doi: 10.18553/jmcp.2008.14.6.553 18693779
30. Tamblyn R, Eguale T, Huang A, Winslade N, Doran P. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med. 2014; 160 (7): 441-450. doi: 10.7326/M13-1705 24687067
31. McClellan C, Lambdin BH, Ali MM, Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018; 86: 90-95. doi: 10.1016/j.addbeh.2018.03.014 29610001